Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
Stopped early · Phase 2
Conditions studied: Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
In brief
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving a monoclonal antibody, such as alemtuzumab, before transplant and tacrolimus and methotrexate after transplant may stop this from happening. PURPOSE: This phase II trial is studying the side effects of donor stem cell transplant and to see how well it works in treating patients with high-risk hematologic cancer.
Key facts
- Study ID
- NCT00818961
- Run by
- Northside Hospital, Inc.
- People needed
- 36
- Starts
- 2005-05-01
- Expected to finish
- 2012-03-01
- Last updated by the study team
- 2013-12-18
Who can join
Age: 40 and older, up to 72. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Blood and Marrow Transplant Group of Georgia — Atlanta, Georgia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.